Evidence map›Paper›PMID 25895126›Full record

ArticleOncotarget2015

Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction.

Zaid Al-Wahab, Ismail Mert, Calvin Tebbe, Jasdeep Chhina, Miriana Hijaz, Robert T Morris, Rouba Ali-Fehmi, Shailendra Giri, Adnan R Munkarah, Ramandeep Rattan

Open access · diamondAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Metformin: A Novel Weapon Against Inflammation.Frontiers in pharmacology · 2021
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zaid Al-WahabWayne State University, Detroit, MI, USA.
Ismail MertWayne State University, Detroit, MI, USA.
Calvin TebbeDivision of Gynecologic Oncology, Department of Women's Health, Henry Ford Hospital, Detroit, MI, USA.
Jasdeep ChhinaDivision of Gynecologic Oncology, Department of Women's Health, Henry Ford Hospital, Detroit, MI, USA.
Miriana HijazDivision of Gynecologic Oncology, Department of Women's Health, Henry Ford Hospital, Detroit, MI, USA.
Robert T MorrisWayne State University, Detroit, MI, USA.
Rouba Ali-FehmiDepartment of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Shailendra GiriDepartment of Neurology, Henry Ford Hospital, Detroit, MI, USA.
Adnan R MunkarahDivision of Gynecologic Oncology, Department of Women's Health, Henry Ford Hospital, Detroit, MI, USA.
Ramandeep RattanDivision of Gynecologic Oncology, Department of Women's Health, Henry Ford Hospital, Detroit, MI, USA.
Henry Ford Hospital · USWayne State University · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caloric restriction (CR) was recently demonstrated by us to restrict ovarian cancer growth in vivo. CR resulted in activation of energy regulating enzymes adenosine monophosphate activated kinase (AMPK) and sirtuin 1 (SIRT1) followed by downstream inhibition of Akt-mTOR. In the present study, we investigated the effects of metformin on ovarian cancer growth in mice fed a high energy diet (HED) and regular diet (RD) and compared them to those seen with CR in an immunocompetent isogeneic mouse model of ovarian cancer. Mice either on RD or HED diet bearing ovarian tumors were treated with 200 mg/kg metformin in drinking water. Metformin treatment in RD and HED mice resulted in a significant reduction in tumor burden in the peritoneum, liver, kidney, spleen and bowel accompanied by decreased levels of growth factors (IGF-1, insulin and leptin), inflammatory cytokines (MCP-1, IL-6) and VEGF in plasma and ascitic fluid, akin to the CR diet mice. Metformin resulted in activation of AMPK and SIRT1 and inhibition of pAkt and pmTOR, similar to CR. Thus metformin can closely mimic CR's tumor suppressing effects by inducing similar metabolic changes, providing further evidence of its potential not only as a therapeutic drug but also as a preventive agent.

Indexed as

Caloric RestrictionAMP-Activated Protein KinasesAnimalsAnticarcinogenic AgentsCell Line, TumorDisease Models, AnimalEnergy MetabolismEnzyme ActivationFemaleInflammation MediatorsIntercellular Signaling Peptides and ProteinsMetforminMice, Inbred C57BLOvarian NeoplasmsPhosphorylationProto-Oncogene Proteins c-aktAMP-Activated Protein KinasesAnticarcinogenic AgentsInflammation MediatorsIntercellular Signaling Peptides and ProteinsMetforminmTOR protein, mouseProto-Oncogene Proteins c-aktSIRT1 protein, humanSirtuin 1TOR Serine-Threonine KinasesAMPKcalorie restrictionmetforminmTORovarian cancer

Identifiers

PMID25895126
PMCPMC4484428
OpenAlexW1884809995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.